ArticleJournal of autism and developmental disorders2026
Vitamin D in Autism Spectrum Disorder: A Critical Systematic Review of Evidence and Methodological Limitations.
Article in Journal of autism and developmental disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A masking effect of vitamin D on ASD symptom severity: mediation by developmental level and altered predictive features in vitamin D insufficiency.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D is discussed in neurodevelopmental and immune pathways relevant to autism spectrum disorder (ASD). This systematic review synthesizes evidence on serum vitamin D status and vitamin D supplementation outcomes in children and adolescents with ASD, with descriptive reporting of one combined vitamin D plus omega-3 arm for context only.
methodsPubMed was searched on 16 August 2024 for observational studies reporting serum 25-hydroxyvitamin D [25(OH)D] and for randomized controlled trials (RCTs) of vitamin D supplementation; the primary narrative synthesis of trial evidence was restricted to double-blind, placebo-controlled studies with the maximum Jadad score (5/5).
resultsEight observational studies met inclusion criteria. Most reported lower 25(OH)D in children with ASD compared with comparator groups, while neonatal findings were mixed across cohorts. Among three placebo-controlled RCTs, one high-dose study reported statistically significant improvements on symptom scales, whereas trials using 2,000 IU/day reported marginal or no effects on ASD-related outcomes. One combined vitamin D plus omega-3 trial arm is summarized descriptively for context.
conclusionCurrent evidence does not support vitamin D supplementation as a general ASD-targeted intervention. Larger, well-controlled trials with prespecified baseline status, standardized outcomes, and safety-focused follow-up are needed to clarify potential subgroup effects and clinical relevance.
Indexed as
Identifiers
42189368What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.